Nanologica AB (publ) (NICA.ST)
SEK 1.21
(-1.63%)
SEK 1.21
(-1.63%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.97 Million SEK | 154.1% |
| 2022 | 1.17 Million SEK | -51.41% |
| 2021 | 2.4 Million SEK | -47.53% |
| 2020 | 4.58 Million SEK | 21.03% |
| 2019 | 3.79 Million SEK | 40.98% |
| 2018 | 2.68 Million SEK | -45.22% |
| 2017 | 4.9 Million SEK | 324.07% |
| 2016 | 1.15 Million SEK | 0.0% |
| 2015 | - SEK | -100.0% |
| 2014 | 1.00 SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 5.03 Million SEK | 69.32% |
| 2024 Q2 | 22.33 Million SEK | 343.6% |
| 2023 Q1 | 1.33 Million SEK | 13.76% |
| 2023 Q3 | 1.56 Million SEK | -12.94% |
| 2023 Q2 | 1.8 Million SEK | 35.31% |
| 2023 Q4 | 2.97 Million SEK | 89.6% |
| 2023 FY | 2.97 Million SEK | 154.1% |
| 2022 Q1 | 1.23 Million SEK | -48.59% |
| 2022 Q4 | 1.17 Million SEK | -14.47% |
| 2022 FY | 1.17 Million SEK | -51.41% |
| 2022 Q3 | 1.36 Million SEK | 9.88% |
| 2022 Q2 | 1.24 Million SEK | 0.57% |
| 2021 Q1 | 5.31 Million SEK | 15.76% |
| 2021 Q4 | 2.4 Million SEK | -45.57% |
| 2021 Q3 | 4.42 Million SEK | -17.06% |
| 2021 FY | 2.4 Million SEK | -47.53% |
| 2021 Q2 | 5.33 Million SEK | 0.41% |
| 2020 Q4 | 4.58 Million SEK | -16.09% |
| 2020 Q3 | 5.46 Million SEK | -35.37% |
| 2020 Q2 | 8.46 Million SEK | 143.09% |
| 2020 FY | 4.58 Million SEK | 21.03% |
| 2020 Q1 | 3.48 Million SEK | -8.19% |
| 2019 Q3 | 4.05 Million SEK | 13.75% |
| 2019 FY | 3.79 Million SEK | 40.98% |
| 2019 Q4 | 3.79 Million SEK | -6.45% |
| 2019 Q2 | 3.56 Million SEK | 8.83% |
| 2019 Q1 | 3.27 Million SEK | 21.73% |
| 2018 Q4 | 2.68 Million SEK | -34.06% |
| 2018 FY | 2.68 Million SEK | -45.22% |
| 2018 Q3 | 4.07 Million SEK | -10.11% |
| 2018 Q2 | 4.53 Million SEK | -3.39% |
| 2018 Q1 | 4.69 Million SEK | -4.34% |
| 2017 FY | 4.9 Million SEK | 324.07% |
| 2017 Q1 | 1.28 Million SEK | 10.9% |
| 2017 Q4 | 4.9 Million SEK | 113.19% |
| 2017 Q2 | 1.33 Million SEK | 3.74% |
| 2017 Q3 | 2.3 Million SEK | 72.9% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | 1.00 SEK | 0.0% |
| 2016 FY | 1.15 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 100.0% |
| 2016 Q4 | 1.15 Million SEK | 115778700.0% |
| 2015 Q4 | -659.71 Thousand SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q2 | 1.00 SEK | 0.0% |
| 2015 FY | - SEK | -100.0% |
| 2014 FY | 1.00 SEK | 0.0% |
| 2014 Q3 | 1.00 SEK | 0.0% |
| 2014 Q4 | 1.00 SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Active Biotech AB (publ) | -2500.00 SEK | 119020.0% |
| Biovica International AB (publ) | 2.19 Million SEK | -35.198% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | -1.79 Million SEK | 265.258% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -189.202% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 765.122% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 5.619% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | 30.537% |
| Intervacc AB (publ) | 10.48 Million SEK | 71.64% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 282.841% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 91.561% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 444.496% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 141.662% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 97.218% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -148649900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 170.972% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 80.054% |
| Camurus AB (publ) | 100.95 Million SEK | 97.055% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -297200.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 67.214% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 93.209% |
| Kancera AB (publ) | -1950.00 SEK | 152561.538% |
| Saniona AB (publ) | 1.00 SEK | -297299900.0% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -297299900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -42.933% |
| Xintela AB (publ) | 398 Thousand SEK | -646.985% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 534 Thousand SEK | -456.742% |
| 2cureX AB (publ) | -1000.00 SEK | 297400.0% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 85.446% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 69.638% |
| Biosergen AB | -4.92 Million SEK | 160.316% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 177.081% |
| NextCell Pharma AB | 545.23 Thousand SEK | -445.267% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -324.714% |
| BioInvent International AB (publ) | 11.84 Million SEK | 74.899% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 1025.75% |
| Alzinova AB (publ) | -3.27 Million SEK | 190.696% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -22.598% |
| Pila Pharma AB (publ) | 1.00 SEK | -297299900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 200167.295% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 26.301% |
| Simris Alg AB (publ) | 1.09 Million SEK | -172.502% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 87.638% |